These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30880569)

  • 1. Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy.
    Johnson ED; Kerrigan K; Butler K; Patel SB
    J Oncol Pharm Pract; 2020 Jan; 26(1):224-227. PubMed ID: 30880569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
    BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
    Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
    J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
    Peiró I; Palmero R; Iglesias P; Díez JJ; Simó-Servat A; Marín JA; Jiménez L; Domingo-Domenech E; Mancho-Fora N; Nadal E; Villabona C
    Endocrine; 2019 Jun; 64(3):605-613. PubMed ID: 30805887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
    Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
    BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angioedema late in the course of adjuvant nivolumab therapy for melanoma.
    Ratra A; Dasanu CA
    J Oncol Pharm Pract; 2020 Jun; 26(4):1019-1021. PubMed ID: 31635547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment.
    Paolini L; Poli C; Blanchard S; Urban T; Croué A; Rousselet MC; Le Roux S; Labarrière N; Jeannin P; Hureaux J
    J Immunother Cancer; 2018 Jun; 6(1):52. PubMed ID: 29898781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
    So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
    J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
    [No Abstract]   [Full Text] [Related]  

  • 13. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
    Gao CA; Weber UM; Peixoto AJ; Weiss SA
    J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma.
    Di Altobrando A; Bruni F; Alessandrini A; Starace M; Misciali C; Piraccini BM
    Dermatol Ther; 2020 May; 33(3):e13363. PubMed ID: 32239596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
    Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
    J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
    Messer A; Drozd B; Glitza IC; Lu H; Patel AB
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
    Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.